RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.
OBJECTIVES: * Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy. * Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen. OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months. PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
Study Type
OBSERVATIONAL
Enrollment
48
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, United States
Toxicity
Number of irreversible severe (grade 3) or life-threatening or lethal (grade 4-5) organ toxicities.
Time frame: 6 months
Time to engraftment
Days from infusion of stem cells to recovery of PMN \> 500/ul for two consecutive determinations, transfusion independence for platelets (\>20,000/ul) and RBCs (Hct \> 25%). The bone marrow function is considered durable if reconstitution persists for at least 6 months.
Time frame: 6 months
Clinical response
Number of participants with a partial response (residual though reduced evidence of active disease) and/or complete response (disappearance of all measurable disease, signs, symptoms, and hematologic or biochemical changes related to the disease, for \>3 months).
Time frame: 6 months
Survival rate
Time frame: 6 months
Number of participants with Graft-versus-host disease
Time frame: 6 months
Time to treatment failure and relapse
Time from day 1 of chemoradiotherapy to transplant-related death or disease relapse.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.